Bromocriptine: A Sympatholytic, D2-dopamine Agonist for the Treatment of Type 2 Diabetes

Ralph A. DeFronzo, MD

Disclosures

Diabetes Care. 2011;34(4):789-794. 

In This Article

Safety and Tolerability

In the Cycloset monotherapy and add-on to sulfonylurea trials,[29] side effects that occurred more commonly in Cycloset versus placebo were nausea (26 vs. 5%), asthenia (15 vs. 8%), constipation (11 vs. 4%), dizziness (11 vs. 6%), and rhinitis (8 vs. 5%). In general, these side effects were mild and transient. Thirteen percent of Cycloset-treated subjects withdrew because of adverse events compared with 3–5% of placebo-treated subjects (P < 0.01). There was no increase in serious adverse events in the Cycloset compared with placebo groups (2.4 vs. 4.3%, respectively). There was no difference in the incidence of hypoglycemia between the Cycloset and placebo-treated groups in any trial.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....